| Abstract | OBJECTIVE: To assess the efficiency of nandrolone decanoate (ND) in the control of anemia in elderly male patients on hemodialysis (HD), and to determine its influence on nutritional parameters. DESIGN: A prospective 6-month study with randomization of patients on recombinant human erythropoietin (rHuEPO) therapy into two groups. Group A: rHuEPO was stopped before starting treatment with ND. Group E: rHuEPO was continued. SETTING: Renal unit, tertiary-care center. PATIENTS: 14 male patients in Group A and 19 patients, 12 males and 7 females, in Group E. INTERVENTIONS: In Group A rHuEPO was stopped and ND 200 mg/I.M. weekly was given over six months. RESULTS: The increase in hemoglobin and hematocrit levels was progressive with ND, and significant differences (p < 0.003) were evident after six months (9.6 +/- 1.0 vs 11.0 +/- 1.4 and 28.9 +/- 4.7 vs 33.0 +/- 4.7, respectively), which remained unmodified in Group E. Group A showed a significant increase in serum creatinine, total protein, transferrin and anthropometric parameters. These parameters remained stable and even presented a tendency to decrease in Group E. There was a significant rise in the concentration of triglycerides and a significant decrease in both HDL-cholesterol and apolipoprotein A-1 in Group A. However, lipoprotein (a) decreased significantly. No significant changes were detected in Group E. CONCLUSIONS: The use of ND would allow us an acceptable treatment of anemia as well as a better nutritional condition in elderly male patients on dialysis. |
| Authors | A Gascón, J J Belvis, F Berisa, E Iglesias, V Estopiñán, J L Teruel
(Affiliation: General Hospital Obispo Polanco, Teruel, Spain.)
|
| Journal | Geriatric nephrology and urology
(Geriatr Nephrol Urol)
Vol. 9
Issue 2
Pg. 67-72
( 1999)
ISSN: 0924-8455 NETHERLANDS |
| PMID | 10518249
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
| Chemical References |
- Anabolic Agents
- Apolipoprotein A-I
- Cholesterol, HDL
- Erythropoietin, Recombinant
- nandrolone decanoate
- Nandrolone
|
| Topics |
- Aged
- Anabolic Agents
(therapeutic use)
- Anemia
(drug therapy)
- Apolipoprotein A-I
(blood)
- Cholesterol, HDL
(blood)
- Erythropoietin, Recombinant
(therapeutic use)
- Female
- Humans
- Male
- Nandrolone
(analogs & derivatives, therapeutic use)
- Prospective Studies
- Renal Dialysis
(adverse effects)
|
